A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATICS HEAD AND NECK SQUAMOUS CELL CARCINOMA

Registry ID

209229

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Start date

2020-02-28

Last update

2019-10-23

Conditions

• SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Related clinical trials

• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PETOSEMTAMAB PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC PD-L1+ HEAD AND NECK SQUAMOUS CELL CARCINOMA.
• A PHASE 3 OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PETOSEMTAMAB COMPARED WITH INVESTIGATOR¿S CHOICE MONOTHERAPY TREATMENT IN PREVIOUSLY TREATED PATIENTS WITH INCURABLE, METASTATIC/RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE DOSTARLIMAB AS SEQUENTIAL THERAPY AFTER CHEMORADIATION IN PARTICIPANTS WITH LOCALLY ADVANCED UNRESECTED HEAD AND NECK SQUAMOUS CELL CARCINOMA
• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) AS SEQUENTIAL THERAPY VERSUS OBSERVATION IN PARTICIPANTS WITH UNRESECTED LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY (EVOLVE-HNSCC)
• A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTOCOL TO EVALUATE NOVEL IMMUNOTHERAPY COMBINATIONS AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

View on source registry